Physician profile
Bryan Abessi
NPI 1104184621
$3,632.50
in general payments reported to CMS, 2019-2025
22 companies · $595 in 2025
The $595 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $292 · 2020: $317 · 2021: $393 · 2022: $543 · 2023: $1,081 · 2024: $412 · 2025: $595.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,088.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,087.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $752.42 | 2019-2025 | Cequa |
| Glaukos Corporation | $426.02 | 2020-2025 | Photrexa Viscous and Photrexa, Photrexa, Ce-Marked Kxla System |
| Allergan, INC. | $409.51 | 2019-2022 | |
| Alcon Vision LLC | $361.29 | 2019-2025 | Clareon, Clareon Panoptix Pro, Tryptyr |
| Sight Sciences, INC. | $265.73 | 2024-2025 | Omni Surgical System, Sion Surgical Instrument, Tearcare System |
| Johnson & Johnson Surgical Vision, INC. | $252.20 | 2021-2023 | Tecnis Iol |
| Abbvie INC. | $219.97 | 2022-2023 | Vuity |
| Oyster Point Pharma, INC. | $195.07 | 2022-2024 | Tyrvaya |
| Aerie Pharmaceuticals, INC. | $165.84 | 2019-2020 | |
| Bausch & Lomb Americas INC. | $118.74 | 2023-2025 | Miebo, Vyzulta, Scoutpro Osmolarity System |
| New World Medical,INC. | $110.15 | 2022 | |
| Ocular Therapeutix, INC. | $81.62 | 2021-2025 | Dextenza |
| Tearlab Corp | $44.38 | 2021-2022 | |
| Dompe US, INC. | $39.34 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $37.62 | 2020-2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $30.40 | 2021-2022 | |
| Shire North American Group INC | $27.60 | 2019 | |
| Lombart Brothers, INC. | $23.66 | 2022 | |
| Harrow Eye, LLC | $20.57 | 2024 | Vevye |
| Tarsus Pharmaceuticals, INC. | $18.17 | 2025 | Xdemvy |
| Biotissue Holdings INC. | $17.38 | 2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $14.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Abessi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.